Induction of humoral and cellular immune responses by antigen-expressing immunostimulatory liposomes

Amidi, Maryam; Helden, Mary J. G. van; Tabataei, Neda Rafiei; Goede, Anna L. de; Schouten, Marijn; Bot, Volkert de; Lanzi, Anastasia; Gruters, Rob A.; Rimmelzwaan, Guus F.; Sijts, Alice J.A.M.; Mastrobattista, Enrico

doi:10.1016/j.jconrel.2012.08.016

Cited by 5 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A long-lasting immune response without toxicity was reported in two groups of the trial. 401 Antigens used with liposomes range from proteins 402 to peptides, 403 RNA, 404 DNA, 405 and synthetic human MUC1 peptides, 406 further establishing the versatility of liposomes as vaccine drug delivery vehicles. The antigen can be encapsulated in the liposome core or presented on the liposome surface via adsorption to the lipid bilayer or with a covalent/noncovalent conjugation to the bilayer surface.…”

Section: Vaccine Deliverymentioning

confidence: 99%

New Developments in Liposomal Drug Delivery

2015

View full text Add to dashboard Cite

Section: Vaccine Deliverymentioning

confidence: 99%

New Developments in Liposomal Drug Delivery

2015

View full text Add to dashboard Cite

“…Vaccination of mice showed that such antigen-producing liposomes elicited higher specific immune responses against the produced antigen than control vaccines [Amidi et al . 2011, 2012].…”

Section: Liposome-based Antigensmentioning

confidence: 99%

Liposomes as vaccine delivery systems: a review of the recent advances

Schwendener

2014

Therapeutic Advances in Vaccines

440

309

View full text Add to dashboard Cite

Liposomes and liposome-derived nanovesicles such as archaeosomes and virosomes have become important carrier systems in vaccine development and the interest for liposome-based vaccines has markedly increased. A key advantage of liposomes, archaeosomes and virosomes in general, and liposome-based vaccine delivery systems in particular, is their versatility and plasticity. Liposome composition and preparation can be chosen to achieve desired features such as selection of lipid, charge, size, size distribution, entrapment and location of antigens or adjuvants. Depending on the chemical properties, water-soluble antigens (proteins, peptides, nucleic acids, carbohydrates, haptens) are entrapped within the aqueous inner space of liposomes, whereas lipophilic compounds (lipopeptides, antigens, adjuvants, linker molecules) are intercalated into the lipid bilayer and antigens or adjuvants can be attached to the liposome surface either by adsorption or stable chemical linking. Coformulations containing different types of antigens or adjuvants can be combined with the parameters mentioned to tailor liposomal vaccines for individual applications. Special emphasis is given in this review to cationic adjuvant liposome vaccine formulations. Examples of vaccines made with CAF01, an adjuvant composed of the synthetic immune-stimulating mycobacterial cordfactor glycolipid trehalose dibehenate as immunomodulator and the cationic membrane forming molecule dimethyl dioctadecylammonium are presented. Other vaccines such as cationic liposome-DNA complexes (CLDCs) and other adjuvants like muramyl dipeptide, monophosphoryl lipid A and listeriolysin O are mentioned as well. The field of liposomes and liposome-based vaccines is vast. Therefore, this review concentrates on recent and relevant studies emphasizing current reports dealing with the most studied antigens and adjuvants, and pertinent examples of vaccines. Studies on liposome-based veterinary vaccines and experimental therapeutic cancer vaccines are also summarized.

show abstract

“…Amidi et al anticipated that the liposomes are artificial microbes which produce specific antigenic response hence can be used as a vaccine delivery system [44]. The admixture of plasmid DNA encoding hsp65 (heat shock protein) in the form of liposome induces a protective immune response and reduces fungal infection and treat the pulmonary fungal infection, paracoccidiomycosis [45].…”

Section: Liposomal Dna Vaccinesmentioning

confidence: 99%

Combined vaccines for prophylaxis of infectious conditions

Shende

Waghchaure

2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

In recent years, the application of vaccines shows limitations, including the high number of vaccine administrations and the fear of safety and effectiveness. In this regard, advanced vaccine products have been developed, like the combined vaccines, or are under development, such as nucleic acid vaccines (DNA and RNA), polymer-based vaccines, etc. Moreover, the possible use of traditional, like aluminium hydroxide and aluminium phosphate, or innovative adjuvants, like monophosphoryl lipid A, polysaccharides and nanoparticulate system, may further increase vaccine effectiveness. This review article focuses on the combined vaccines, which, especially when they are associated with adjuvants, reduce the dosing frequency, and prolong the duration of action, thus providing better vaccine coverage. Marketed preparations, like Typhim Vi, Peda typh and Boostrix showed better vaccine coverage for diseases like typhoid, tetanus, diphtheria and acellular pertussis. The future aspect for the development of combined vaccines will protect not only against infectious diseases but likely even against various infectious conditions, like pneumonia, meningococcal infection and respiratory syncytial virus infection.

show abstract

Induction of humoral and cellular immune responses by antigen-expressing immunostimulatory liposomes

Cited by 5 publications

References 38 publications

New Developments in Liposomal Drug Delivery

New Developments in Liposomal Drug Delivery

Liposomes as vaccine delivery systems: a review of the recent advances

Combined vaccines for prophylaxis of infectious conditions

Contact Info

Product

Resources

About